GenMark Diagnostics (GNMK) falls 6.5% AH on top of 8.35% during the regular session. The company says it now sees FY13 revenue of ~$30M versus the $35M it originally estimated. GNMK cites "additional uncertainties relating to the future revenue contribution from its largest customer" (previous).
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs